Indeed, the pharmacological activation of p53 drives MDSC differentiation to Ly6C+CD103+ DCs, which are essential to enhance a CD8+ T cell anti-tumour immune response during ICT [216]. The gene discussed is CD8A; the disease is neoplasm.